WEST PHARM.SVCS DL-,25WW

WEST PHARM.SVCS DL-,25

209.0EURD
+0.4+0.19%
At close at 12:01 GMT
EUR
No trades
See on Supercharts

WPS fundamentals

Key facts

Market capitalization‪15.15 B‬EUR
Founded1923
Employees (FY)‪10.6 K‬
CEOEric Mark Green
About

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Ownership
‪‪72.30 M‬‬
Free Float shares
‪‪71.88 M‬‬ (99.41%)
Closely held shares
‪‪428.69 K‬‬ (0.59%)
Free Float shares
‪‪71.88 M‬‬ (99.41%)
Closely held shares
‪‪428.69 K‬‬ (0.59%)
Capital structure
Market cap
‪‪15.15 B‬‬
Debt
‪‪294.91 M‬‬
Cash & equivalents
‪‪468.11 M‬‬
Enterprise value
‪‪14.98 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪15.15 B‬‬
Price to earning ratio (P/E)
32.69x
Price to sales ratio (P/S)
5.54x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
32.69x
Price to sales ratio (P/S)
5.54x
Valuation ratios
‪0.00‬
‪2.60‬
‪5.20‬
‪7.80‬
‪10.40‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪15%‬
‪16%‬
‪17%‬
‪18%‬
‪19%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Proprietary Products
Contract-Manufactured Products
By country
Period: 2024
United States
Other European Countries
Germany
Other
Ireland
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Actual
Estimate
Earnings
Next:Apr 24, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
12.26%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.37%
Next payment
0.20
Next ex-date
Apr 30, 2025
Dividend history
‪0.10%‬
‪0.16%‬
‪0.22%‬
‪0.28%‬
‪0.34%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.20‬
‪0.40‬
‪0.60‬
‪0.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪550.00 M‬‬
‪‪1.10 B‬‬
‪‪1.65 B‬‬
‪‪2.20 B‬‬
Assets
Liabilities